Molecular Testing

  • March 16, 2023  

    A New Biomarker to Optimize Immunotherapy for People with Cancer

    With: Scott Tomlins, MD, PhD

    Immunotherapy—a type of treatment that harnesses a patient’s own immune system to fight cancer—has been a “game changer” for many patients. It can be difficult, however, to predict whether or not a given person would benefit from immunotherapy, especially when it comes to drugs that target the immune system molecules PD-1 and PD-L1. Our Curious Dr. George asks Scott Tomlins, MD, PhD, Co-founder and… Read more »

  • January 28, 2023  

    Using Live Cells from Patients to Find the Right Cancer Drug

    With: Clifford A. Reid, PhD

    Today, many cancer patients benefit from targeted drugs that are matched to the distinct genetic mutations found in their tumors. However, especially in late-stage cancer, this “precision oncology” strategy has not proven to be as transformative as people once hoped. Here, Curious Dr. George asks Clifford A. Reid, PhD, CEO of Travera, how his company is addressing this problem. Curious Dr. George: The U.S.… Read more »

  • December 11, 2022  

    Taking Your Cancer Management to the Next Level: Webinar Recap

    Sarah Stanley

    There is no teacher quite like personal experience. Whether you are dealing with your own diagnosis or helping someone else, you become deeply familiar with cancer’s many practical and emotional challenges. Facing cancer can inspire people to help others navigate their own cancer journey. On November 9, 2022, Cancer Commons presented a free webinar featuring three passionate advocates who have drawn on their own… Read more »

  • October 11, 2022  

    Demystifying Cancer Biomarkers: Webinar Recap

    Sarah Stanley

    If you have just been diagnosed with cancer, or are facing recurrence, progression, or a change in treatment, you may feel bombarded with new information and advice. At some point, a clinician or even a well-meaning friend may urge you to have “biomarker testing” done. This phrase can be especially confusing when dealing with the stress of trying to understand a new diagnosis, a… Read more »

  • August 23, 2022  

    Using AI and Drug Testing to Design Personalized Cancer Drug Combos

    With: Noah Berlow, PhDDiana Azzam, PhD

    Advanced cancer treatment often involves combining multiple drugs. But with a huge number of possible combinations, it is difficult to know which mix might work best for each patient. Here, our Curious Dr. George asks two leaders to describe how the company First Ascent Biomedical is addressing this challenge. Curious Dr. George: The U.S. Food and Drug Administration (FDA) has approved many thousands of… Read more »

  • August 15, 2022  
  • June 10, 2022  

    NCI Overview of Uterine Cancer Bookmark

    George Lundberg, MD

    The National Cancer Institute provides this online overview of uterine cancer that is up-to date, comprehensive, and written specifically for patients.

    .

  • June 2, 2022  

    Harnessing Each Patient’s Data to Help Many More

    With: Kaumudi Bhawe, PhD

    At Cancer Commons, we don’t just help people navigate cancer treatment; we learn from everyone we help. Here, our Curious Dr. George asks Cancer Commons Clinical Scientist Kaumudi Bhawe, PhD, to share how new knowledge can be captured from every patient to help many more. Curious Dr. George: Cancer Commons has accumulated in-depth data on many hundreds of patients with various cancers. Because of the… Read more »

  • April 13, 2022  

    Cancer Commons Adapts to Remain True to Our Mission

    With: Shelley Frisbie

    People facing advanced cancer come to Cancer Commons to ensure they have all the information they need to make their best-possible cancer care decisions. Here, Curious Dr. George asks our CFO & COO Shelley Frisbie about recent updates to our organization. Curious Dr. George: You have been the CFO of Cancer Commons for some time and recently added the COO title and duties to… Read more »

  • March 22, 2022  

    Immunotherapy Approvals Signal a Need for Molecular Testing in Endometrial Cancer Bookmark

    George Lundberg, MD

    Molecular testing often guides choices of immunotherapy, as illustrated in this OncLive story about endometrial cancer.

    .